Research News and Research

RSS

Experts: Americans get too many tests, too much treatment

"Too much cancer screening, too many heart tests, too many cesarean sections. A spate of recent reports suggest that too many Americans -- maybe even President Barack Obama -- are being overtreated." Defensive medicine and a culture focusing on medical technology have lead to overtesting but "now new evidence and guidelines are recommending a step back and more thorough doctor-patient conversations about risks and benefits."

12 Mar 2010

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

BeaconEquity.com announces an investment report featuring biotechnology company BioSante Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

12 Mar 2010

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

Ardea Biosciences, Inc. (Nasdaq: RDEA) a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments, announced fourth quarter and full-year 2009 financial results and provided key upcoming clinical development milestones and financial guidance for 2010.

12 Mar 2010

$Bisphosphonate treatments may affect bone quality and increase risk of atypical fractures of femur$

Bisphosphonate treatments may affect bone quality and increase risk of atypical fractures of femur

Bisphosphonate treatments, proven to enhance bone density and reduce fracture incidence in post-menopausal women, may adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years, according to preliminary research presented today at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons.

12 Mar 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for full year and fourth quarter, ended December 31, 2009. These results are included in the Company’s Annual Report on Form 10-K which has been filed with the SEC.

12 Mar 2010

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

GTC Biotherapeutics, Inc. today reported its financial results for the fourth quarter and fiscal year ended January 3, 2010. The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.

12 Mar 2010

Prevention of choking hazards in food: Safe, children oriented packaging and design needed

While choking hazards in toys have been widely publicized and addressed by the Consumer Product Safety Commission (CPSC), ironically choking hazards in food have lacked federal attention despite the fact that food is far more likely to go into a child’s mouth.

12 Mar 2010

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2009.

12 Mar 2010

Cytori Therapeutics reports total revenues of $14.7M for 2009

Cytori Therapeutics is reporting its financial results for the year ended December 31, 2009.

From Evident Corporation - Life Sciences 12 Mar 2010

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Arena Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

12 Mar 2010

Illinois Governor proposes unacceptable, harmful cuts to human services

The FY11 proposed budget Governor Quinn released on March 10, 2010 includes unacceptable cuts to human services – totaling $276 million. These cuts fall on the most vulnerable in our state – seniors, people with mental illness and disabilities, victims of violence, and children. Such cuts will harm individuals and families, result in the loss of jobs across Illinois and further weaken our state's economy.

12 Mar 2010

StockPreacher.com announces investment report featuring Generex Biotechnology

StockPreacher.com announces an investment report featuring Generex Biotechnology Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Mar 2010

Tackling childhood obesity: Chidren need to be involved in physical activity program planning process

Getting children involved in finding ways to become more physically active can not only make them more aware of local recreational opportunities, but can even help increase their own physical activity.

12 Mar 2010

Achillion Pharmaceuticals reports net loss of $6.7M for three months ended December 31, 2009

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and twelve months ended December 31, 2009.

12 Mar 2010

Vermont: Only state to pass bill mandating coverage of colon cancer screening

Progress towards nationwide, state-mandated coverage of colon cancer screening according to accepted medical guidelines has slowed to a crawl as state legislators await the outcome of the health care reform debate at the federal level, a coalition of public health associations and medical professional societies reported today. With a better grade for only a single state – Vermont – 2009 marks the least improvement in a single year since the Colorectal Cancer Legislation Report Card began in 2004.

12 Mar 2010

University of Tennessee CST effectively detects cognitive abnormalities associated with Alzheimer's disease

Early detection is key to more effective treatment for Alzheimer's disease and other forms of cognitive impairment, and new research shows that a test developed at the University of Tennessee is more than 95 percent effective in detecting cognitive abnormalities associated with these diseases.

12 Mar 2010

BeaconEquity.com announces investment report featuring NexMed

BeaconEquity.com announces an investment report featuring NexMed Inc. (Nasdaq:NEXM). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Mar 2010

First Editon: March 12, 2010

Today's headlines focus on Democratic leaders' ongoing efforts to reach health care consensus and push a bill forward. Meanwhile, the GOP is ready to use the majority party's overhaul vote as a political tool in upcoming elections.

12 Mar 2010

More U.S. investment in diplomacy, development needed, say former military leaders

A group of former U.S. military leaders have joined "recent calls by Defense Secretary Robert Gates and Chairman of the Joint Chiefs of Staff Adm. Michael Mullen to expand U.S. civilian capacities to reduce dependence on the military," Politico's Laura Rozen reports on her blog.

12 Mar 2010

New SpermCheck Fertility home test kit for sperm level measurement

Infertility affects between 10 and 15 percent of couples worldwide. Surprisingly, problems with male fertility account for approximately 50 percent of infertility cases.

12 Mar 2010

Research News and Research

Experts: Americans get too many tests, too much treatment

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

Bisphosphonate treatments may affect bone quality and increase risk of atypical fractures of femur

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

Prevention of choking hazards in food: Safe, children oriented packaging and design needed

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

Cytori Therapeutics reports total revenues of $14.7M for 2009

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Illinois Governor proposes unacceptable, harmful cuts to human services

StockPreacher.com announces investment report featuring Generex Biotechnology

Tackling childhood obesity: Chidren need to be involved in physical activity program planning process

Achillion Pharmaceuticals reports net loss of $6.7M for three months ended December 31, 2009

Vermont: Only state to pass bill mandating coverage of colon cancer screening

University of Tennessee CST effectively detects cognitive abnormalities associated with Alzheimer's disease

BeaconEquity.com announces investment report featuring NexMed

First Editon: March 12, 2010

More U.S. investment in diplomacy, development needed, say former military leaders

New SpermCheck Fertility home test kit for sperm level measurement

A guide to advancing biotherapeutic research eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence